HighTower Advisors
IRLA

HighTower Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

HighTower Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,643
Closed -$1.1M – 3908
2025
Q4 		$1.1M Buy
1,643
+100
+6% +$50.3K ﹤0.01% 2050
2025
Q3 		$503K Hold
1,543
– – ﹤0.01% 2615
2025
Q2 		$509K Sell
1,543
-175
-10% -$40K ﹤0.01% 2506
2025
Q1 		$457K Buy
1,718
+10
+0.6% +$3.05K ﹤0.01% 2538
2024
Q4 		$639K Hold
1,708
– – ﹤0.01% 2283
2024
Q3 		$273K Hold
1,708
– – ﹤0.01% 2884
2024
Q2 		$251K Buy
+1,708
New +$309K ﹤0.01% 2866

Other funds holding IRLA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HighTower Advisors's IRLA Position: Q1 2026 in Review

HighTower Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2026, closing a stake of 1,643 shares — an estimated $1.1M sold.

HighTower Advisors first reported a position in IRLA in Q2 2024 and held it in 7 quarters. The position peaked at $1.1M in Q4 2025. 43 funds tracked by Wall St. Rank hold IRLA as of Q1 2026.

  • HighTower Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • HighTower Advisors sold 1,643 IRulya Therapeutics Inc. Common Stock shares in Q1 2026, an estimated $1.1M.
  • HighTower Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2024 and held it in 7 quarters.
  • HighTower Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $1.1M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.